When $Hims & Hers Health Inc.(HIMS)$ stock dropped to under $15 early this year the company was reviled for being untrustworthy and a one-trick pony in compounded GLP-1s. Those times of panic were an opportunity for long-term investors to understand the strategy and why AndrewDudum would do seemingly crazy things that upset Big Pharma. That’s what the two articles I wrote in those moments explained. But few went through the exercise of understanding Hims strategy or what the potential outcomes of a patent lawsuit really was. For those of you who read Asymmetric Investing in those brutal months and stayed invested or doubled down (like I did in the Asymmetric Portfolio) its days like this that show why research and conviction matter. Drowning o